Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology ConferencesGlobeNewsWire · 6 days ago
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical TrialGlobeNewsWire · Oct 9, 2026
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVRGlobeNewsWire · Sep 24, 2026
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of “Moderate Buy” by BrokeragesDefense World · Sep 21, 2026
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United StatesGlobeNewsWire · Sep 3, 2026
Milestone Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewsWire · Sep 2, 2026Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.20 | -$0.21 | Miss |
| May 13, 2026 | $0.06 | -$0.20 | Miss |
| Mar 20, 2026 | -$0.18 | -$0.16 | Beat |
| Nov 12, 2025 | -$0.17 | -$0.12 | Beat |
| Aug 12, 2025 | -$0.18 | -$0.20 | Miss |
| May 14, 2025 | -$0.19 | -$0.31 | Miss |